Wegovy and belly fat: does it target the right kind?

Why belly fat is the decision point for many people starting Wegovy

There's a meaningful difference between subcutaneous fat (the soft layer just under the skin) and visceral fat, which sits around the abdominal organs and carries a distinct set of metabolic risks: insulin resistance, raised triglycerides, increased cardiovascular risk. When people ask whether Wegovy reduces belly fat, what they often mean is: will it touch the fat that matters most to health, not just to appearance?

The short answer, based on trial data, is yes. In the STEP 1 trial, published in the New England Journal of Medicine, participants taking semaglutide 2.4mg lost an average of around 15% of body weight over 68 weeks alongside lifestyle changes, and waist circumference fell substantially. Because visceral fat is metabolically active and tends to be shed earlier in significant weight loss, reductions in abdominal girth typically reflect real losses in the deeper fat stores, not just subcutaneous tissue.

That said, no medicine reshapes the body selectively. Many people researching how semaglutide affects belly fat find that it creates a calorie deficit by reducing appetite and slowing gastric emptying, with the body then drawing on fat stores according to individual genetics, hormonal profile, and baseline body composition. Most people notice changes across the abdomen, face, and limbs rather than one area alone. If abdominal fat is your primary concern, that context is worth raising when you discuss eligibility, our clinical team considers the full picture, not just a single number.

Which Wegovy dose matters for fat around the middle

Wegovy is titrated gradually, the starting dose is intended to let your body adjust before any therapeutic effect on weight becomes significant. Fat loss accelerates as the dose increases toward the maintenance level, which was 2.4mg weekly in the original licence (and can now go higher following the MHRA's approval of a 7.2mg dose in 2026). Expecting visible changes at the earliest doses, within the first few weeks, sets people up for frustration. Most of the meaningful waist-circumference reduction in trials happened over months, not the first fortnight.

The Wegovy overview on our treatment page explains the full dosing journey in plain terms. People often want to understand what Wegovy does to belly fat specifically, and the honest answer is that the cumulative effect of sustained appetite reduction over six months or more is what drives changes in abdominal fat, not a single injection. Consistency matters more than the specific dose at any given week.

One practical note on timing: people sometimes ask about starting around a holiday or a busy period. Starting treatment when routine is disrupted can make it harder to notice early side effects properly or to maintain the lifestyle support that improves outcomes, something to factor in when you're thinking about when to begin.

The limits of targeting one body region, and what shapes the outcome

Spot reduction is a persistent myth across every area of health and fitness, and Wegovy is no exception. Semaglutide reduces energy intake systemically; where that deficit is drawn from depends on factors you cannot fully control. People with a higher proportion of visceral fat often see a greater proportional reduction there early on, because visceral fat is more metabolically responsive. But genetics, baseline hormonal status, and how much lean mass someone is preserving all influence the final shape of the result.

This is one reason the NHS medicine information for semaglutide frames Wegovy as a medicine to be used alongside diet and physical activity changes, not independently of them. Resistance training, adequate protein intake, and consistent movement influence whether weight lost comes disproportionately from fat or from lean tissue, and that matters for long-term abdominal composition. If you're still weighing up whether Wegovy can genuinely help with belly fat in your situation, a prescriber or dietitian can help translate the evidence into a practical approach. There's more on the landscape of weight-loss medicines and what determines outcomes on our weight-loss treatments overview.

Prescription, eligibility, and next steps

Wegovy is a prescription-only medicine, which means clinical assessment comes first. The licensed criteria cover adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as high blood pressure, type 2 diabetes or raised cholesterol. Lower thresholds can apply for some ethnic backgrounds under UK guidance. Meeting those criteria doesn't guarantee a prescription, a prescriber looks at your full health picture, including any contraindications and your goals.

At nume, every consultation is reviewed the same day by a GPhC-registered Independent Prescriber. There's a useful set of questions people ask before starting on our FAQ page, including a closer look at whether Wegovy helps lose belly fat and what that realistically looks like over time. If you'd like to explore whether Wegovy suits your situation (including whether abdominal fat reduction is a realistic part of what to expect) check your eligibility with a free consultation. The process takes a few minutes, costs nothing, and puts a real clinician's assessment between you and a prescription decision.